- Home
- LLAP vs TLSI Comparison
LLAP vs TLSI Comparison
Compare LLAP & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLAP
- TLSI
- Stock Information
- Founded
- LLAP 2013
- TLSI 2010
- Country
- LLAP United States
- TLSI United States
- Employees
- LLAP N/A
- TLSI N/A
- Industry
- LLAP Military/Government/Technical
- TLSI Medical Specialities
- Sector
- LLAP Industrials
- TLSI Health Care
- Exchange
- LLAP Nasdaq
- TLSI Nasdaq
- Market Cap
- LLAP 165.7M
- TLSI 166.8M
- IPO Year
- LLAP N/A
- TLSI N/A
- Fundamental
- Price
- LLAP $0.24
- TLSI $5.00
- Analyst Decision
- LLAP Buy
- TLSI Strong Buy
- Analyst Count
- LLAP 3
- TLSI 2
- Target Price
- LLAP $2.58
- TLSI $14.00
- AVG Volume (30 Days)
- LLAP 9.4M
- TLSI 64.0K
- Earning Date
- LLAP 08-12-2024
- TLSI 08-14-2024
- Dividend Yield
- LLAP N/A
- TLSI N/A
- EPS Growth
- LLAP N/A
- TLSI N/A
- EPS
- LLAP N/A
- TLSI N/A
- Revenue
- LLAP $133,107,000.00
- TLSI $24,736,000.00
- Revenue This Year
- LLAP $8.71
- TLSI $61.24
- Revenue Next Year
- LLAP $34.59
- TLSI $47.32
- P/E Ratio
- LLAP N/A
- TLSI N/A
- Revenue Growth
- LLAP 10.75
- TLSI 67.75
- 52 Week Low
- LLAP $0.23
- TLSI $3.32
- 52 Week High
- LLAP $1.62
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- LLAP 24.59
- TLSI 38.30
- Support Level
- LLAP $0.24
- TLSI $4.80
- Resistance Level
- LLAP $0.30
- TLSI $5.47
- Average True Range (ATR)
- LLAP 0.02
- TLSI 0.35
- MACD
- LLAP 0.01
- TLSI -0.05
- Stochastic Oscillator
- LLAP 2.95
- TLSI 16.82
About LLAP Terran Orbital Corporation
Terran Orbital Corp is a manufacturer of satellite products primarily serving the aerospace and defense industries. The company provide end-to-end satellite solutions by combining satellite design, production, launch planning, mission operations, and on-orbit support to meet the needs of our military, civil, and commercial customers. Geographically company operates in United States and Europe. Majority of the revenue is generated from United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.